Skip to main content
SpringerLink
Log in

New and Improved Techniques for Vaccine Production

  • Conference paper
Progress in Vaccinology

Part of the book series: Progress in Vaccinology ((VACCINOLOGY,volume 2))

  • 102 Accesses

Abstract

Vaccines represent the most spectacular success of applied immunology. Since the discoveries of Jenner and Pasteur, large numbers of vaccines have been developed, and today more than 30 products are regularly and widely used in humans. Over the past decade discoveries and technological progress have, however, transformed the production possibilities of bacterial and viral vaccines, and the aim of this presentation is to illustrate these new and improved vaccine production techniques using a few examples. These limited examples are drawn mainly from our experience at the Institut Mérieux and cover the fields of both bacterial and viral vaccines.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson P, Smith DH: Isolation of the capsular polysaccharide from the culture supernatant of Haemophilus influenzae b. Infect Immun 1977; 15: 472–477.

    PubMed  CAS  Google Scholar 

  2. Austrian R, Douglas RM, Schiffman G, et al: Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physician 1976; 89: 184–194.

    CAS  Google Scholar 

  3. Ayme G, Donikian R, Mynard MC, Lagrandeur G: Production and controls of serogroup A Neisseria meningitidis polysaccharide vaccine, in Table Ronde sur l’Immunoprophylaxie de la Méningite Cérébrospinale, Saint-Paul de Vence, France. Lyon, Fondation Mérieux, 1973, pp 4–30.

    Google Scholar 

  4. Cadoz M, Armand J, Arminjon F, et al: A new 23 valent pneumococcal vaccine: immunogenicity and reactogenicity in adults. J Biol Stand 1985; 13: 261–265.

    Article  PubMed  CAS  Google Scholar 

  5. Cadoz M, Arminjon F, Quentin-Millet MJ, Armand J: Safety and immunogenicity of Mérieux acellular pertussis vaccines in adult volunteers. Presented at: Workshop on Acellular Pertussis Vaccines Organized by the Interagency Group to Monitor Vaccine Development, CDC, FDA, NIH. Bethesda, 1986.

    Google Scholar 

  6. Chadli A, Merieux C, Arrouji A, Ajjan N: Study of the efficacy of a vaccine produced from rabies virus cultivated on Vero cells, in Vodopija I, et al (eds): Improvements in Rabies Post-exposure Treatment Zagreb, Institute of Public Health, 1985, pp 129–136.

    Google Scholar 

  7. Clemens JD, Sack DA, Harris JR, et al: Field trial of oral cholera vaccines in Bangladesh. Lancet 1986; 2: 124–127.

    Article  PubMed  CAS  Google Scholar 

  8. Court G, Nguyen C, Tayot JL: Purification of tetanus toxin by affinity chromatography on porous silica beads derivatized with polysialogangliosides, in Sixth International Conference on Tetanus. Lyon, Fondation Mérieux, 1982, pp 331–345.

    Google Scholar 

  9. Dureux B, Canton PH, Gerard A, et al: Rabies vaccine for human use, cultivated on Vero cells. Lancet 1986; 2: 98.

    Article  PubMed  CAS  Google Scholar 

  10. Fournier P, Montagnon B, Vincent-Falquet JC, et al: A new vaccine produced from rabies virus cultivated on Vero cells, in Vodopija I, et al (eds): Improvements in Rabies Postexposure Treatment. Zagreb, Institute of Public Health, 1985, pp 115–121.

    Google Scholar 

  11. Fredman P, Nilsson O, Tayot JL, Svennerholm L: Separation of ganglioside on a new type of anion-exchange resin. Biochim Biophys Acta 1980; 618: 42–52.

    PubMed  CAS  Google Scholar 

  12. Gotschlich EC, Liu TY, Artenstein MS: Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J Exp Med 1969; 129: 1349–1365.

    Article  PubMed  CAS  Google Scholar 

  13. Granström M, Granström G, Gillenius P, Askelöf P: Neutralizing antibodies to pertussis toxin in whooping cough. J Infect Dis 1985; 151: 646–649.

    Article  PubMed  Google Scholar 

  14. Holmgren J, Svennerholm AM, Lönnroth I, et al: Development of improved cholera vaccine based on subunit toxoid. Nature 1977; 269: 602–604.

    Article  PubMed  CAS  Google Scholar 

  15. Homma T, Kanki PJ, King NW, et al: Lymphoma in macaques: association with virus of human T lymphotrophic family. Science 1984; 225: 716–718.

    Article  PubMed  CAS  Google Scholar 

  16. Manclark CR: Proceedings of the Fourth International Symposium on Pertussis. Dev Biol Stand 1986; 61: 3–576.

    Google Scholar 

  17. Montagnon BJ, Fanget B, Nicolas AJ: The large scale cultivation of Vero cells in microcarrier culture for virus vaccine production—preliminary results for killed poliovirus vaccine. Dev Biol Stand 1981; 47: 55–64.

    PubMed  CAS  Google Scholar 

  18. Montagnon B, Vincent-Falquet JC, Fanget B: Thousand litre scale microcarrier culture of Vero cells for killed polio virus vaccine: promising results. Dev Biol Stand 1984; 55: 37–42.

    Google Scholar 

  19. Montagnon B, Fanget B, Vincent-Falquet JC: Industrial scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier. Rev Infect Dis 1984; 6 (suppl 2): S341–344.

    Article  PubMed  Google Scholar 

  20. Montagnon BJ, Martin R, Barraud B, et al: Residual Vero cell DNA and inactivated polio vaccine: detection by DNA-DNA molecular hybridization, in Hope. HE, Petricciani JC (eds): Abnormal Cells, New Products and Risk. Gaithersburg, Maryland, Tissue Culture Association, 1985, pp 82–89.

    Google Scholar 

  21. Montagnon B, Fanget B, Fournier P, et al: Vaccin rage PVRV: pureté et stabilité, in La Rage et la Brucellose dans le Bassin Méditerranéen et la Péninsule Arabe, Montpellier, France. Lyon, Fondation Mérieux, 1986, pp 147–152.

    Google Scholar 

  22. Olin P : Clinical trials of acellular pertussis vaccines in Sweden: an attempt to solve the problem of pertussis vaccination. Presented at the Sclavo International Conference on Bacterial Vaccines and Local Immunity, Sienna, Italy, November 17–19, 1986.

    Google Scholar 

  23. Peltola H, Käythy H, Sivonen A: Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977; 60: 730–737.

    PubMed  CAS  Google Scholar 

  24. Petricciani JC: Old issues confront biotechnology and new products. Vaccine 1984; 2: 235–236.

    Article  Google Scholar 

  25. Robbins JB, Austrian R, Lee CJ, et al: Considerations for formulating the second generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross reactive types within groups. J Infect Dis 1983; 148: 1136–1159.

    Article  PubMed  CAS  Google Scholar 

  26. Roumiantzeff M, Ajjan N, Branche R, et al: Rabies vaccine produced in cell culture: production, control and clinical results, in Kurstak E, Al-Nakib W, Kurstak C (eds): Applied Virology I. New York, Academic Press, 1984, pp 241–296.

    Google Scholar 

  27. Roumiantzeff M, Armand J, Thoinet M, Taylor JL: Production and use of vaccines: technology of vaccine production, in Bell R, Torrigiani G, (eds): New Approaches to Vaccine Development. Basel, Schwabe, 1984, pp 477–493.

    Google Scholar 

  28. Roumiantzeff M, Ajjan N, Montagnon B, Vincent-Falquet JC: Rabies vaccines produced in cell culture. Ann Inst Pasteur Virol 1985; 136E: 413–424.

    Article  Google Scholar 

  29. Roumiantzeff M, Ajjan N, Vincent-Falquet JC: Experience in pre-exposure vaccination, in Rev Infect Dis 1988; 4.

    Google Scholar 

  30. Sato Y, Kimura M, Fukumi H: Development of a pertussis component vaccine in Japan. Lancet 1984; 1: 122–126.

    Article  PubMed  CAS  Google Scholar 

  31. Schneerson R, Barrera O, Sutton A, Robbins JB: Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 1980; 152: 361–376.

    Article  PubMed  CAS  Google Scholar 

  32. Suntharasamai P, Warreil MJ, Warrell DA, et al: New purified Vero-cell vaccine prevents rabies in patients bitten by rabid animals. Lancet 1986; 2: 129–131.

    Article  PubMed  CAS  Google Scholar 

  33. Svennerholm AM, Jertborn M, Gothefors L, et al: Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J Infect Dis 1984; 149: 884–893.

    Article  PubMed  CAS  Google Scholar 

  34. Tardy M, Tayot JL, Roumiantzeff M, Plan R: Immunoaffinity chromatography on derivatives of porous silica beads: industrial extraction of antitetanus antibodies from placental blood and plasma, in Epton R (ed): Chromatography of Synthetic and Biological Polymers. Chichester, Ellis Horwood, 1978, vol 2, pp 298–313.

    Google Scholar 

  35. Tayot JL, Tardy M, Gattel P, et al: Industrial ion exchange chromatography of proteins on DEAE-Dextran derivates of porous silica beads, in Epton R (ed): Chromatography of Synthetic and Biological Polymers. Chichester, Ellis Horwood, 1978, vol 2, pp 95–110.

    Google Scholar 

  36. Tayot JL, Tardy M: Isolation of cholera toxin by affinity chromatography on porous silica beads covalently coupled ganglioside GM,, in Svennerholm L, Dreyfus H, Urban PF (eds): Structure and Function of Gangliosides. New York, Plenum 1980, pp 471–478.

    Google Scholar 

  37. Tayot JL, Holmgren J, Svennerholm L, et al: Receptor-specific large-scale purification of cholera toxin on silica beads derivatized with lyso GM, ganglioside. Eur J Biochem 1981; 113: 249–258.

    Article  PubMed  CAS  Google Scholar 

  38. Tiesjema RH, Beuvery EC, Tepas BJ: Enhanced stability of meningococcal polysaccharide vaccines by using lactose as a menstrum for lyophilisation. Bull WHO 1977; 55: 43–48.

    PubMed  CAS  Google Scholar 

  39. Van Steenis G, Van Wezel AL: Use of ATG-treated new-born rat for in vivo tumorigenicity testing of cell substrates. Dev Biol Stand 1982; 50: 37–46.

    Google Scholar 

  40. Van Wezel AL: Growth of cell strains and primary cells on microcarrier in homogeneous culture. Nature 1967; 216: 64–65.

    Article  PubMed  Google Scholar 

  41. Wiktor TJ, Fernandes MV, Koprowski H: Cultivation of rabies virus in human diploid cell strain WI 38. J Immunol 1964; 93: 353–356.

    PubMed  CAS  Google Scholar 

  42. WHO Expert Committee on Biological Standardization: Requirements for poliomyelitis vaccine (inactivated). WHO Tech Rep Ser 1982;673:annex 2.

    Google Scholar 

  43. WHO: T-Lymphotropic retroviruses of non-human primates. Weekly Epidemiol Rec 1985; 60: 269–270.

    Google Scholar 

  44. WHO Expert Committee on Biological Standardization: Requirements for rabies vaccine (inactivated) for human use produced in continuous all lines. WHO Tech Rep Ser 1987;760:annex 9.

    Google Scholar 

Download references

Authors
  1. M. Roumiantzeff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Armand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Arminjon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Montagnon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Cadoz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. National Institute of Immunology, JNU Complex, Shahid Jeet Singh Marg, 110 067, New Delhi, India

    G. P. Talwar

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag New York Inc.

About this paper

Cite this paper

Roumiantzeff, M., Armand, J., Arminjon, F., Montagnon, B., Cadoz, M. (1989). New and Improved Techniques for Vaccine Production. In: Talwar, G.P. (eds) Progress in Vaccinology. Progress in Vaccinology, vol 2. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-3508-8_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-3508-8_4

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-96734-9

  • Online ISBN: 978-1-4612-3508-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation